Janssen Pharmaceutica Nv

Ortho-Mcneil Pharmaceutical Corp.

Michael Renzi

Linda K Jolliffe

Francis Farrell

Dana L Johnson

Carlos Plata-Salaman

Virginia L Smith-Swintosky

Navneeth Thirumalai

Methods of treating diseases of the nervous system by administration of compositions having the neurological therapeutic activity of human erythropoietin are disclosed. These compositions include therapeutic agents such as peptides, peptide dimers, polypeptides, and proteins that have the full range of biological activity of human erythropoietin or only certain biological activities of erythropoietin. Improved therapeutic regimens where the erythropoietin is administered at concentrations below those required to stimulate hematopoiesis are also provided.

Neuroprotective peptides

The effect of EPO on the phosphorylation of the EPO receptor, the activation of the MAP Kinase pathway, and the expression of SHP-1 were analyzed. EPO was observed to cause a decrease in the expression of its negative regulator SHP-1. The decrease observed at both the mRNA and protein level was dose dependent and persisted as long as 24 hr following EPO treatment. EPO can down regulate the expression of its own negative regulator as a means for increased potency in neurons. Assays were generated to identify compounds that are useful in regulating SHP1 activity in neural cells.

Methods for SHP1 mediated neuroprotection

Growing community of inventors

Harleysville, PA, United States of America

Michael Renzi